Strategic opportunity Target large medical device players and distributors leveraging LARIAT technology. Potential sales alignment with AtriCure or similar entities seeking complementary venous drainage/left atrial appendage management capabilities, given historical acquisition activity.

Regulatory momentum Capitalize on multi-region regulatory clearance (US, Europe, Canada) to approach hospitals and integrated delivery networks expanding LAA closure options, highlighting CE Mark expansions and ongoing aMAZE trial to support adoption.

Clinical traction Promote ongoing randomized controlled trial results and clinical evidence development to drive payer discussions and adoption in centers focusing on persistent or longstanding persistent atrial fibrillation treatments.

Market readiness Position SentreHEART as a nimble partner for mid-size to large institutions seeking innovative suture delivery solutions, emphasizing regulatory clearance, CE labeling expansion, and proven integration into existing electrophysiology workflows.

Strategic partnerships Leverage past funding and acquisition history to open dialogues with potential investors or strategic buyers, while identifying distributor channels and service partners to accelerate market uptake in key geographies.